This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Medroxyprogesterone acetate, Depo-subQ Provera 104
Description: Depo-Provera Contraceptive Injection (CI) contains medroxyprogesteroneacetate, a derivative of progesterone, as its active ingredient. Depo-Provera, dosed to women every 3 months, inhibits the secretion of gonadotropins and prevents follicular maturation and ovulation. This results in endometrial thinning and enables its contraceptive effect. The drug is also available in a different formulation under the label Depo-subQ Provera 104.
Pink Sheet Upjohn Depo-Provera
Pink Sheet Canadian review of Upjohn’s Depo-Provera
Additional information available to subscribers only: